FrancophonIA/ELRC3.0 huggingface dataset:
English: Inactivated Bordetella bronchiseptica, strain 833CER: ............................................ 9.8 BbCC Recombinant Type D Pasteurella multocida toxin (PMTr): ................................... ≥ 1 MED63
Estonian: inaktiveeritud Bordetella bronchiseptica tüvi 833CER: ............................................ 9,8 BbCC rekombinantne D-tüüpi Pasteurella multocida toksiin (PMTr): .............................. ≥ 1 MED63
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE BOTTLE AND VIAL LABEL
Estonian: SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PUDELI JA VIAALI ETIKETT
English: Pigs (sows and gilts).
Estonian: Siga (emis ja kesik).
English: 20 ml, 50 ml, 100 ml and 250 ml Polyethylene (PET) bottles closed with a rubber stopper and aluminium cap.
Estonian: 20 ml, 50 ml, 100 ml ja 250 ml polüetüleenpudelid, mis on suletud kummikorgi ja lumiiniumkaanega.
English: For passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with Bordetella bronchiseptica and Pasteurella multocida infections during the fattening period.
Estonian: Põrsaste passiivseks kaitsmiseks ternespiima kaudu pärast emiste ja kesikute aktiivset immuniseerimist progresseeruva ja mitteprogresseeruva atroofilise riniidi kliiniliste nähtude ja kahjustuste vähendamiseks, samuti Bordetella bronchiseptica ja Pasteurella multocida infektsioonidega seotud kehamassi languse vähendamiseks nuumaperioodil.
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Estonian: Kasutamata veterinaarravimid võinende jäätmed tuleb hävitada vastavalt kohalikule seadusandlusele.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated ) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Estonian: - Väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l loomal 10-st ravitud loomast) - Sage (rohkem kui 1-l, kuid vähem kui 10-l loomal 100-st ravitud loomast) - Aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l loomal 1000-st ravitud loomast) - Harv (rohkem kui 1-l, kuid vähem kui 10-l loomal 10000-st ravitud loomast) - Väga harv (vähem kui 1-l loomal 10000-st ravitud loomast, kaasaarvatud üksikjuhud)
English: Disodium phosphate dodecahydrate Potassium dihydrogen phosphate Sodium chloride
Estonian: Abiainete loetelu alumiiniumhüdroksiid DEAE-dekstraan ženšenn formaldehüüd simetikoon dinaatriumfosfaat dodekahüdraat kaaliumdivesinikfosfaat naatriumkloriid kaaliumkloriid süstevesi
English: MANUFACTURER<S> RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII VABASTAMISE EEST VASTUTAVAD TOOTJA<D B. TARNIMIS- JA KASUTAMISTINGIMUSED VÕI PIIRANGUD C. RAVIMJÄÄKIDE PIIRNORMID
English: Type II colourless glass vials of 50 ml and 100 ml .
Estonian: I tüüpi värvuseta 20 ml klaasviaalid II tüüpi värvuseta 50 ml ja 100 ml klaasviaalid
English: Shelf life after first opening the immediate packaging: 10 hours stored at room temperature.
Estonian: Kõlblikkusaeg pärast vahetu pakendi esmast avamist: säilib 10 tundi toatemperatuuril.
English: Adjuvants:
Estonian: Abiaine:
English: Discoloration of muscular fibres of the inoculation site (0.5 cm wide x 2 cm long) may be observed at necropsy in 10% of animals.
Estonian: 10% loomade lahangul võib täheldada lihaskiudude värvimuutust inokulatsioonikohal (laius 0,5 cm x pikkus 2 cm).
English: Common adverse reactions:
Estonian: Sagedasemad kõrvaltoimeid:
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJAD JA RAVIMIPARTII VABASTAMISE EEST VASTUTAVAD TOOTJA<D
English: To stimulate active immunity in order to provide passive immunity to the progeny against atrophic rhinitis associated with Bordetella bronchiseptica and Pasteurella multocida infections.
Estonian: Aktiivse immuunsuse stimuleerimiseks järglastele Bordetella bronchiseptica ja Pasteurella multocida infektsioonidega seotud atroofilise riniidi vastase passiivse immuunsuse andmiseks.
English: Shelf life after first opening the immediate packaging: 10 hours stored at 15 ºC to 25 ºC.
Estonian: Kõlblikkusaeg pärast vahetu pakendi esmast avamist: säilib 10 tundi temperatuuril 15 ºC kuni 25 ºC.
English: Formaldehyde
Estonian: RAVIMVORM
English: - Transient local reactions may occur after the administration of one dose of vaccine.
Estonian: - Pärast ühe vaktsiiniannuse manustamist võib tekkida mööduvaid paikseid reaktsioone.
English: Pack sizes: - Cardboard box with 1 or 10 glass vials of 10 doses.
Estonian: Pakendi suurused: - pappkarp 1 või 10 klaasviaaliga, mis sisaldavad 10 annust; - pappkarp 1 klaasviaaliga, mis sisaldab 25 annust; - pappkarp 1 klaasviaaliga, mis sisaldab 50 annust;
English: EXP {month/ year} Once opened, use within a 10-hour period, stored at 15 ºC to 25 ºC.
Estonian: Kõlblik kuni {kuu/aasta} Pärast avamist kasutada ära 10 tunni jooksul, säilib temperatuuril 15 ºC kuni 25 ºC.
English: - Cardboard box with 1 PET bottle of 125 doses.
Estonian: - pappkarp 1 või 10 polüetüleenpudeliga, mis sisaldab 10 annust; - pappkarp 1 polüetüleenpudeliga, mis sisaldab 25 annust; - pappkarp 1 polüetüleenpudeliga, mis sisaldab 50 annust; - pappkarp 1 polüetüleenpudeliga, mis sisaldab 125 annust.
English: In case of accidental self-injection only a minor injection site reaction is expected.
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule Juhuslikul ravimi süstimisel iseendale võib tekkida vaid vähene reaktsioon süstekohal.
English: Formaldehyde .................................................................................................................. 0.8 mg For the full list of excipients, see section 6.1.
Estonian: Formaldehüüd.............................................................................................................. 0,8 mg Abiainete täielik loetelu on esitatud punktis 6.1.
English: Name and address of the manufacturer
 responsible for batch release
Estonian: Ravimipartii vabastamise eest vastutava<te> tootja<te> nimi <nimed> ja aadress<id> Laboratorios Hipra, S.A.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Estonian: Ettevaatusabinõud veterinaarravimit loomale manustavale isikule: Juhuslikul ravimi süstimisel iseendale võib tekkida vaid vähene reaktsioon süstekohal.
English: The company that applied for authorisation is Portola Pharma UK Limited.
Estonian: Müügiluba taotles ettevõte Portola Pharma UK Limited.
English: EMA/501901/2018EMA/501901/2018EMEA/H/C/004309
Estonian: EMA/501901/2018 EMEA/H/C/004309
English: If you are in a clinical trial and need more information about your treatment, contact the doctor who is treating you in the clinical trial.
Estonian: Kui osalete ravimi kliinilises uuringus ja vajate oma ravi kohta lisateavet, pöörduge palun arsti poole, kes teile ravi määras.
English: The company presented the results of one main study involving over 7,500 adults who had been admitted to hospital for a recent medical illness.
Estonian: Ettevõte esitas ühe põhiuuringu tulemused; uuring hõlmas üle 7500 täiskasvanu, kes viibisid hiljutise haiguse tõttu haiglaravil.
English: What is Dexxience?
Estonian: Mis on Dexxience?
English: After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the marketing authorisation on 26 July 2018.
Estonian: Pärast taotluse põhjenduste arutamist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 26. juulil 2018.
English: Refusal of the marketing authorisation for Dexxience (betrixaban) EMA/501901/2018
Estonian: Dexxience (betriksabaan) müügiloa andmisest keeldumine EMA/501901/2018
English: Thrombin is needed for blood to clot.
Estonian: Trombiin on vajalik vere hüübimiseks.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Dexxience did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee sel ajal arvamusel, et Dexxience kasulikkus ei ole suurem kui sellega kaasnevad riskid, ja soovitas müügiloa andmisest keelduda.
English: It was to be used in adults admitted to hospital for the treatment of a recent medical illness.
Estonian: Seda kavatseti kasutada täiskasvanutel, kes viibivad hiljutise haiguse ravimiseks haiglaravil.
English: Blood clots that start off in the veins can move to another part of the body such as the lungs and the brain where they can cause severe problems with breathing or stroke.
Estonian: Veenides tekkinud trombid võivad liikuda teise kehaossa, näiteks kopsu või ajusse, kus need võivad põhjustada tõsiseid hingamisprobleeme või insulti.
English: This was considered an important concern given that the medicine was expected to be used in patients with serious underlying conditions for whom any episode of bleeding could have serious consequences, and Dexxience's long persistence in the body could complicate management of bleeding.
Estonian: Seda peeti oluliseks probleemiks, sest ravimit kavatseti kasutada olemasoleva raske haigusega patsientidel, kellel võib mis tahes verejooksuepisood põhjustada raskeid tagajärgi, ning Dexxience pikk organismis püsimise aeg võib muuta verejooksu ohjamise keerulisemaks.
English: Also, patients treated with Dexxience had more episodes of bleeding than those treated with the comparator medicine.
Estonian: Samuti oli Dexxiencega ravitud patsientidel rohkem verejooksuepisoode kui võrdlusravimiga ravitud patsientidel.
English: On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Dexxience, intended for the prevention of venous thromboembolism.
Estonian: 22. märtsil 2018 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades keelduda andmast ravimi Dexxience müügiluba.
English: How does Dexxience work?
Estonian: Kuidas Dexxience toimib?
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Dexxience.
Estonian: Ettevõte teatas inimravimite komiteele, et keeldumine ei mõjuta praegu Dexxience kliinilistes uuringutes osalevaid patsiente.
English: Dexxience is a medicine that contains the active substance betrixaban.
Estonian: Dexxience on ravim, mis sisaldab toimeainena betriksabaani.
English: The CHMP considered that the main study did not satisfactorily show Dexxience's effectiveness when used for preventing blood clots in patients admitted to hospital for recent medical illness.
Estonian: Inimravimite komitee arvas, et põhiuuringuga ei tõendatud piisavalt Dexxience efektiivsust trombide ennetamisel hiljutise haiguse tõttu haiglaravil viibivatel patsientidel.
English: By blocking factor Xa, the medicine reduces the levels of thrombin in the blood and this reduces the risk of blood clots forming in blood vessels.
Estonian: Xahüübimisfaktorit blokeerides vähendab ravim vere trombiinisisaldust, mis omakorda vähendab trombide tekke riski veresoontes.
English: The patients were at high risk of venous thromboembolism because of their age, presence of a protein indicating a blood clot, previous blood clots, cancer and lack of mobility during hospital treatment.
Estonian: Patsientidel oli suur venoosse trombemboolia oht järgmistel põhjustel: vanus, trombi olemasolule viitava valgu esinemine veres, varem esinenud trombid, vähk ja haiglaravist tulenev vähene liikuvus.
English: These patients may be at high risk of blood clots because of reduced mobility during their hospital treatment as well as other underlying conditions that increase the risk.
Estonian: Neil patsientidel võib olla suurem trombide tekke oht, sest nende liikuvus on haiglaravi ajal vähenenud ning ohtu võivad suurendada ka muud olemasolevad seisundid.
English: The main measure of effectiveness was the occurrence of deep vein thrombosis (blood clot in a deep vein, usually in the leg), or of pulmonary embolism (blood clot in the lung), or death from a blood clot.
Estonian: Efektiivsuse põhinäitaja oli süvaveenitromboosi (trombi teke süvaveenis, tavaliselt jalas) või kopsuemboolia (tromb kopsus) esinemine või surm trombi tõttu.
English: Refusal of the marketing authorisation for Dexxience (betrixaban)
Estonian: Dexxience (betriksabaan) müügiloa andmisest keeldumine
English: Dexxience was expected to be used to prevent venous thromboembolism (formation of blood clots in veins).
Estonian: Dexxiencet kavatseti kasutada venoosse trombemboolia (trombide teke veenides) ennetamiseks.
English: What was Dexxience expected to be used for?
Estonian: Milleks kavatseti Dexxiencet kasutada?
English: Treatment with Dexxience was compared with enoxaparin, another medicine for preventing blood clots.
Estonian: Ravi Dexxiencega võrreldi enoksapariiniga, mis on samuti trombide teket ennetav ravim.
English: EMA/501901/2018
Estonian: juuli 2018
English: The active substance in Dexxience, betrixaban, is a ‘factor Xa inhibitor'.
Estonian: Dexxience toimeaine betriksabaan on Xa-hüübimisfaktori inhibiitor, mis tähendab, et see pärsib Xahüübimisfaktorit, trombiini moodustumises osalevat valku.
English: The full EPAR and risk management plan summary for Pemetrexed Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Pemetrexed Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Pemetrexed Accord is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Pemetrexed Accordi võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Pemetrexed Accord?
Estonian: Mis meetmed võetakse, et tagada Pemetrexed Accordi ohutu ja efektiivne kasutamine?
English: It is given once every three weeks as an infusion lasting 10 minutes.
Estonian: Ravimit Pemetrexed Accord manustatakse iga kolme nädala järel 10-minutilise infusioonina.
English: The Committee recommended that Pemetrexed Accord be approved for use in the EU.
Estonian: Komitee soovitas Pemetrexed Accordi kasutamise Euroopa Liidus heaks kiita.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pemetrexed Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Pemetrexed Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: No additional studies were needed as Pemetrexed Accord is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Alimta.
Estonian: Lisauuringuid ei olnud vaja, sest Pemetrexed Accord on infusioonina manustatav geneeriline ravim, mis sisaldab sama toimeainet kui võrdlusravim Alimta.
English: To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Accord.
Estonian: Kõrvalnähtude vähendamiseks tuleb patsiendil võtta kortikosteroide (põletikuvastane ravim) ja foolhapet (teatud vitamiin) ning talle tuleb Pemetrexed Accordiga toimuva ravi ajal süstida vitamiini B12.
English: Pemetrexed Accord is a cancer medicine used to treat two types of lung cancer:
Estonian: Pemetrexed Accord on vähiravim, mida kasutatakse kaht tüüpi kopsuvähi raviks:
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pemetrexed Accord has been shown to be comparable to Alimta.
Estonian: Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Pemetrexed Accord sarnane toime ravimiga Alimta.
English: What is Pemetrexed Accord and what is it used for?
Estonian: Mis on Pemetrexed Accord ja milleks seda kasutatakse?
English: Because Pemetrexed Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Pemetrexed Accord on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It is not intended to provide practical advice on how to use Pemetrexed Accord.
Estonian: Hindamisaruandes ei anta Pemetrexed Accordi kasutamise praktilisi nõuandeid.
English: This means that Pemetrexed Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Alimta.
Estonian: See tähendab, et Pemetrexed Accord on sarnane võrdlusravimiga Alimta, millel juba on Euroopa Liidus müügiluba.
English: • advanced non-small-cell lung cancer of the kind known as ‘non-squamous', where it is used either in combination with cisplatin in previously untreated patients or on its own in patients who have previously received cancer treatment.
Estonian: • kaugelearenenud mitteväikerakk-kopsuvähi muu kui lamerakuline vorm, kusjuures ravimit kasutatakse varem ravimata patsientidel koos tsisplatiiniga või ainsa ravimina patsientidel, kes on varem saanud vähiravi.
English: For practical information about using Pemetrexed Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Accordi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Pemetrexed Accord.
Estonian: See on ravimi Pemetrexed Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: Pemetrexed Accord pemetrexed
Estonian: Pemetrexed Accord pemetrekseed
English: For more information about treatment with Pemetrexed Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pemetrexed Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It can also be used as a maintenance treatment in patients who have received a platinum-based chemotherapy.
Estonian: Ravimit Pemetrexed Accord tohib kasutada säilitusraviks ka patsientidel, kes on saanud plaatinapõhist keemiaravi.
English: When Pemetrexed Accord is given with cisplatin, an ‘anti-emetic' medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Estonian: Kui Pemetrexed Accordi kasutatakse koos tsisplatiiniga, tuleb enne või pärast tsisplatiini annuse manustamist anda patsiendile antiemeetikumi (oksendamise ennetamiseks) ja vedelikke (dehüdratsiooni ennetamiseks).
English: Pemetrexed Accord contains the active substance pemetrexed.
Estonian: Pemetrexed Accord sisaldab toimeainena pemetrekseedi.
English: The medicine can only be obtained with a prescription and should only be given under the supervision of a doctor who is qualified in the use of cancer medicines.
Estonian: Pemetrexed Accord on retseptiravim ja seda tohib manustada üksnes vähiravi kasutamises kogenud arsti järelevalve all.
English: The active substance in Pemetrexed Accord, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Estonian: Pemetrexed Accordi toimeaine pemetrekseed on antimetaboliitide rühma kuuluv tsütotoksiline ravim (ravim, mis hävitab poolduvaid rakke, näiteks vähirakke).
English: Therefore, the CHMP's view was that, as for Alimta, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu Alimta korral, ületab ka ravimi Pemetrexed Accord kasulikkus sellega kaasnevad riskid.
English: Why is Pemetrexed Accord approved?
Estonian: Miks Pemetrexed Accord heaks kiideti?
English: Pemetrexed Accord is a ‘generic medicine'.
Estonian: Pemetrexed Accord on geneeriline ravim.
English: How has Pemetrexed Accord been studied?
Estonian: Kuidas Pemetrexed Accordi uuriti?
English: How is Pemetrexed Accord used?
Estonian: Kuidas Pemetrexed Accordi kasutatakse?
English: Other information about Pemetrexed Accord
Estonian: Muu teave Pemetrexed Accordi kohta
English: Pemetrexed Accord is available as a powder that is made up into a solution for infusion (drip) into a vein.
Estonian: Ravimit Pemetrexed Accord turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
English: What are the benefits and risks of Pemetrexed Accord?
Estonian: Milles seisneb Pemetrexed Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: Commission decision date: 23/11/2017.
Estonian: Komisjoni otsuse kuupäev: 23.11.2017.
English: The review of gadolinium contrast agents was initiated on 17 March 2016 at the request of the European Commission, under Article 31 of Directive 2001/83/EC.
Estonian: Gadoliiniumipõhiste kontrastainete läbivaatamine algas 17. märtsil 2016 Euroopa Komisjoni taotlusel vastavalt direktiivi 2001/83/EÜ artiklile 31.
English: • If you have any questions about your scan, speak to your doctor.
Estonian: • Kui teil on uuringu kohta küsimusi, pidage nõu oma arstiga.
English: The final recommendations have been sent to the European Commission, which issued a final legally binding decision applicable in all EU Member States.
Estonian: Lõplikud soovitused edastati Euroopa Komisjonile, kes tegi õiguslikult siduva lõpliku otsuse, mida kohaldatakse kõigis Euroopa Liidu liikmesriikides.
English: As a result of this interaction, the water molecules give a stronger signal, helping to obtain a brighter image.
Estonian: Selle koostoime tulemusena annavad veemolekulid tugevama signaali, mis aitab saada kontrastsema pildi.
English: The review was first carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations in March 2017.
Estonian: Esmalt vaatas teabe läbi inimravimite ohutusprobleemide hindamise eest vastutav ravimiohutuse riskihindamise komitee, kes koostas soovitused 2017. aasta märtsis.
English: Following a request from companies concerned, the PRAC re-examined its initial recommendation.
Estonian: Asjaomaste ettevõtete taotlusel vaatas ravimiohutuse riskihindamise komitee oma esmased soovitused uuesti läbi.
English: • Healthcare professionals should always use the lowest dose that provides sufficient enhancement for diagnosis.
Estonian: • Tervishoiutöötajad peavad alati kasutama väikseimat annust, mis tagab diagnoosimiseks piisava kontrasteerimise.
English: The final stage of the review procedure was the adoption by the European Commission of a legally binding decision applicable in all EU Member States.
Estonian: Läbivaatamismenetluse viimases etapis võttis Euroopa Komisjon vastu kõigis Euroopa Liidu liikmesriikides kehtiva õiguslikult siduva otsuse.
English: restrict use to liver scans
Estonian: piirata kasutamisega maksauuringutes